ContractSangamo Therapeutics, Inc • November 4th, 2020 • Biological products, (no disgnostic substances)
[*] = Certain confidential information contained in this document, marked by brackets, is omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
COLLABORATION AND LICENSE AGREEMENT by and between Sangamo Therapeutics, Inc. and Novartis Institutes for BioMedical Research, Inc. July 27, 2020Collaboration and License Agreement • November 4th, 2020 • Sangamo Therapeutics, Inc • Biological products, (no disgnostic substances) • New York
This Collaboration and License Agreement (this “Agreement”) is made as of July 27, 2020 (the “Effective Date”), by and between Sangamo Therapeutics, Inc., a Delaware corporation having an office at 501 Canal Blvd., Suite A100, Richmond, CA 94804 (“Sangamo”), and Novartis Institutes for BioMedical Research, Inc., a Delaware corporation having an office at 250 Massachusetts Avenue, Cambridge, MA 02139 (“Novartis”). Novartis and Sangamo are referred to in this Agreement individually as a “Party” and collectively as the “Parties”.
